Recent Finacing
Recent Raise
Artizan Biosciences uses a proprietary IgA-SEQ platform to identify disease-driving intestinal bacteria, develop targeted microbiome therapies for IBD and other indications, and maintains a 1,500-sample biobank.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Artizan.
